Dihydrofolate reductase-thymidylate synthase (DHFR-TS) is a well-validated antifolate drug target in certain pathogenic apicomplexans, but not in the genusBabesia gibsoni, the causative agent of canine babesiosis, is an important protozoan parasite that poses a major clinical health problem in dogs worldwide (19,29,43). Due to the emergence of resistance and failure of antibabesia agents to eliminate the parasite (5), novel chemotherapeutics with better potency and acceptable safety margins are required to treat the infection. To develop novel chemotherapeutics for apicomplexans related to Babesia, such as the Plasmodium parasites, many studies have focused on well-validated molecular targets, including the dihydrofolate reductase (DHFR) enzyme (10,22,30,39), and to a lesser extent the thymidylate synthase (TS) enzyme (20,25). The DHFR and TS domains are expressed as individual monofunctional enzymes in mammals and bacteria (21,36,41); however, in protozoans (and some plants), DHFR and TS exist as a bifunctional enzyme in which they are expressed on a single polypeptide chain (11,23,35). The DHFR domain is a validated target for chemotherapy of infectious diseases (42) and cancer (17) because it is important for the proliferation of cells due to its function in DNA biosynthesis and cell replication.The DHFR enzyme catalyzes the NADPH-dependent reduction of dihydrofolic acid (DHF) to tetrahydrofolate (4), an essential cofactor in the de novo biosynthesis of nucleotidic bases of DNA, while the TS domain catalyzes the reductive methylation of dUMP to dTMP with concomitant conversion of 5,10-methylenetetrahydrofolate to DHF (8). Therefore, the disruption of DHFR activity by antifolates depletes the reduced folate pool, thus blocking de novo dTMP biosynthesis by the TS enzyme and eventually inhibiting cell multiplication, leading to parasite death. Although antifolates inhibit the activities of bifunctional DHFR-TS enzymes of some pathogenic apicomplexan protozoans and disrupt folate metabolism (42), it has not been shown whether these drugs could also inhibit the activity of the corresponding enzyme in the genus Babesia, which includes the pathogen B. gibsoni.Furthermore, the results of earlier studies of the inhibition of the growth of Babesia bovis in vitro by various antifolates (33) and the inhibition of Babesia equi, as well as Babesia caballi, by pyrimethamine (31) suggested disruption of DHFR-TS activity only. Even in a case where the B. bovis dhfr-ts gene had been isolated and the resistance mechanism to pyrimethamine elucidated (16),